Phibro Animal Health Corporation

1 day ago · zacks.com

SEI, SDRL and PAHC made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on September 21st, 2026.

4 days ago · zacks.com

Investors interested in stocks from the Medical - Products sector have probably already heard of Phibro Animal Health (PAHC) and Haemonetics (HAE). But which of these two stocks presents investors with the better value opportunity right now?

11 days ago · zacks.com

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

20 days ago · zacks.com

Investors interested in stocks from the Medical - Products sector have probably already heard of Phibro Animal Health (PAHC) and LeMaitre Vascular (LMAT). But which of these two stocks is more attractive to value investors?

26 days ago · seekingalpha.com

Phibro Animal Health Corporation (PAHC) Q4 2026 Earnings Call Transcript

26 days ago · marketbeat.com

Phibro Animal Health NASDAQ: PAHC reported record fiscal 2026 sales and a sharp increase in adjusted EBITDA, supported by growth in its Animal Health and Mineral Nutrition businesses, the integration of its acquired Zoetis medicated feed additive portfolio, and operational initiatives under its Phibro Forward program.

27 days ago · zacks.com

Although the revenue and EPS for Phibro (PAHC) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

27 days ago · zacks.com

Phibro Animal Health (PAHC) came out with quarterly earnings of $0.85 per share, beating the Zacks Consensus Estimate of $0.72 per share. This compares to earnings of $0.57 per share a year ago.

27 days ago · businesswire.com

TEANECK, N.J.--(BUSINESS WIRE)--Phibro Animal Health Corporation (Nasdaq: PAHC) (“Phibro” or the “Company”) today announced financial results for its fourth quarter and fiscal year ended June 30, 2026 and provided its financial guidance for the fiscal year ending June 30, 2027. Highlights for the three months ended June 30, 2026 (compared to the three months ended June 30, 2025) – Net sales of $396.7 million, an increase of $18.1 million, or 5% – Net income of $21.7 million, an increase of $4.5.

1 month ago · zacks.com

Besides Wall Street's top-and-bottom-line estimates for Phibro (PAHC), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2026.